Adaptive Dose-Escalated Stereotactic Body Radiation Therapy for Men with Intermediate- or High-Risk Prostate Cancer

What this Trial Is About

Researchers are evaluating adaptive stereotactic body radiation therapy SBRT as a treatment for adults with intermediate- and favorable high-risk prostate cancer. This study aims to determine the highest safe dose of adaptive SBRT, how well it targets the prostate while reducing radiation to nearby organs, and its effects on side effects and quality of life during and after treatment over a five-year period. Participants will receive adaptive SBRT every other day for a total of 5 treatment sessions, usually completed within 2 to 3 weeks. After treatment, there will be a follow-up phone call at about 6 weeks to check on side effects and wellbeing. Participants will also have clinic visits for tests and check-ups at 90 days post-treatment, then every 3 months for the first year, and every 6 months thereafter. Throughout the study, researchers will assess treatment-related toxicities occurring within 90 days, biochemical progression, local failure, distant metastasis, and PSA response up to 5 years. They will also monitor urinary, bowel, and sexual function changes using EPIC-26 scores at various intervals. Safety monitoring includes evaluating treatment planning criteria and side effects during and after treatment, with participant involvement lasting up to 5 years.

Adaptive Radiation Therapy for Men With Intermediate- or High-Risk Prostate Cancer